Retatrutide vs Cagrisema
Which Is Right for You? Complete Comparison (2026)
Retatrutide vs CagriSema comparison — Eli Lilly triple GLP-1/GIP/glucagon agonist vs Novo Nordisk GLP-1+amylin combination, Phase 3 race.
Retatrutide vs Cagrisema: At a Glance
Retatrutide
- ✓Triple agonist: GIP + GLP-1 + glucagon receptors
- ✓Glucagon component increases energy expenditure and fat oxidation
- ✓~24% weight loss at 48 weeks in phase 2 (12 mg dose)
- ✓Phase 3 trials ongoing — not yet FDA-approved
- ✓Developed by Eli Lilly
Cagrisema
- ✓Combination: cagrilintide (amylin analogue) + semaglutide (GLP-1)
- ✓Amylin + GLP-1 dual satiety pathway activation
- ✓~22.7% weight loss in phase 2 (vs 15.8% semaglutide alone)
- ✓Single weekly injection combining both agents
- ✓Phase 3 REDEFINE trials ongoing — Novo Nordisk
Detailed Comparison
| Feature | Retatrutide | Cagrisema |
|---|---|---|
| Mechanism | Triple GIP/GLP-1/glucagon receptor agonist | Amylin/GLP-1 combination |
| Dosing | 1-12 mg SC weekly (phase 2 doses) | Cagrilintide 2.4 mg + semaglutide 2.4 mg SC weekly |
| Administration | Subcutaneous injection weekly | Subcutaneous injection weekly |
| Half-life | ~6 days | Cagrilintide ~7 days; semaglutide ~7 days |
| FDA Status | Not FDA-approved — phase 3 clinical trials | Not FDA-approved — phase 3 clinical trials |
| Key Trial | Jastreboff AM et al. NEJM 2023 — phase 2 obesity trial | Frias JP et al. Lancet 2023 — phase 2 combination trial |
| Side Effects | Nausea, diarrhea, vomiting, constipation (similar to other incretins) | GI effects similar to semaglutide; injection site reactions |
Which Should You Choose?
Retatrutide (triple gip/glp-1/glucagon receptor agonist) and CagriSema (Cagrilintide + Semaglutide) (amylin/glp-1 combination) serve different clinical roles despite both being in the Triple incretin agonist space. Retatrutide first triple incretin agonist targeting gip, glp-1, and glucagon receptors. CagriSema (Cagrilintide + Semaglutide) fixed-dose combination of cagrilintide (long-acting amylin analogue) and semaglutide (glp-1 agonist) that targets two satiety pathways for enhanced weight loss.
Whichever you choose, track your protocol in Shotlee to build clean data for dose optimization and outcomes comparison.
Track Both in Shotlee
Shotlee supports tracking any medication or peptide. Compare your results across different protocols with clean dose logs and outcome data.
Making an Informed Choice Between Retatrutide and Cagrisema
Choosing between Retatrutide and Cagrisema depends on multiple individual factors including your specific health goals, tolerance profile, insurance coverage, and prescriber recommendation. While clinical trial data provides population-level efficacy and safety comparisons, your personal response may differ based on genetics, baseline health, concurrent conditions, and lifestyle factors. Use this comparison as a starting framework and discuss the specifics with your healthcare provider.
Head-to-head clinical trial data between Retatrutide and Cagrisema is the gold standard for comparison, but such direct comparisons are not always available for every pair of compounds. Where head-to-head data is lacking, cross-trial comparisons provide useful but imperfect approximations — differences in patient populations, trial design, and endpoint definitions mean that numbers from separate trials are not directly interchangeable. Keep this context in mind when evaluating the comparison data presented here.
Tracking your personal response data in Shotlee is particularly valuable when switching between medications or considering a change. By documenting your outcomes on your current protocol — including efficacy metrics, side effect profile, adherence rate, and quality of life measures — you create an objective baseline for comparison if you transition to the alternative compound. This data transforms a subjective switching decision into an evidence-based protocol optimization.
Retatrutide vs Cagrisema: Common Questions
Retatrutide is a triple gip/glp-1/glucagon receptor agonist while CagriSema (Cagrilintide + Semaglutide) is an amylin/glp-1 combination. They differ in mechanism, dosing, and clinical evidence. Your choice should depend on your specific goals and medical history.
Switching should be done under medical supervision. Your prescriber can advise on transition protocols. Track both in Shotlee for comparison data.
Retatrutide works as a triple gip/glp-1/glucagon receptor agonist (1-12 mg SC weekly (phase 2 doses)), while CagriSema (Cagrilintide + Semaglutide) is an amylin/glp-1 combination (Cagrilintide 2.4 mg + semaglutide 2.4 mg SC weekly). They have different half-lives (~6 days vs Cagrilintide ~7 days; semaglutide ~7 days), side effect profiles, and levels of clinical evidence.
Yes. Shotlee supports tracking any medication or peptide. You can compare your results across different protocols.
Neither is universally better — the right choice depends on your individual health profile, treatment goals, side effect tolerance, insurance coverage, and prescriber recommendation. Clinical trial data shows efficacy differences in specific populations, but personal response varies. Track your experience with either medication in Shotlee to generate objective comparison data with your healthcare provider.
Switching between these medications should be done under medical supervision. Your prescriber will consider factors including your current response, reason for switching, dose equivalence, and transition timing. Use Shotlee to document your outcomes on the current medication so you have a clear baseline for comparison after switching.
References
- [1]Clinical TrialJastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526.
- [2]Clinical TrialFrias JP et al. Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with subcutaneous semaglutide 2.4 mg (CagriSema). Lancet. 2023;402(10403):720-730.
Track Retatrutide or Cagrisema in Shotlee
Free dose tracking, side effect logging, and outcome comparison for any medication protocol.
🚀 Use Shotlee for Free